glp 1 lawsuit Lipsitz, Ponterio & Comerford Lawsuit highlights the dangers of
Description
They are primarily prescribed for managing chronic metabolic conditions like Type 2 diabetes and clinical obesity
FAQs Who is not a good candidate for GLP-1
10.1016/j.jclinane.2023.111091 [DOI] [PubMed] 23.Santos LB, Mizubuti GB, da Silva LM, Silveira SQ, Nersessian RSF, Abib ACV et al (2024) Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: a retrospective single center observational study
Among those, only semaglutide and liraglutide carry specific FDA approvals for obesity
